Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Insider Sells $10,666.56 in Stock

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) insider Steven P. Coen sold 1,084 shares of the stock in a transaction on Thursday, July 17th. The stock was sold at an average price of $9.84, for a total value of $10,666.56. Following the sale, the insider owned 10,679 shares in the company, valued at approximately $105,081.36. This represents a 9.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Ginkgo Bioworks Stock Up 11.6%

Shares of DNA stock traded up $1.18 during trading hours on Monday, hitting $11.31. 2,601,646 shares of the company's stock traded hands, compared to its average volume of 1,435,516. The stock's fifty day simple moving average is $8.94 and its two-hundred day simple moving average is $9.14. Ginkgo Bioworks Holdings, Inc. has a 12-month low of $5.00 and a 12-month high of $16.85. The stock has a market cap of $661.68 million, a price-to-earnings ratio of -1.23 and a beta of 1.48.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.35). The company had revenue of $48.32 million for the quarter, compared to the consensus estimate of $38.70 million. Ginkgo Bioworks had a negative net margin of 198.84% and a negative return on equity of 52.35%. On average, equities analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ginkgo Bioworks

Hedge funds and other institutional investors have recently modified their holdings of the business. US Bancorp DE lifted its stake in shares of Ginkgo Bioworks by 43.5% during the first quarter. US Bancorp DE now owns 6,302 shares of the company's stock worth $36,000 after buying an additional 1,911 shares during the period. KLP Kapitalforvaltning AS purchased a new position in Ginkgo Bioworks in the fourth quarter valued at $46,000. CWM LLC grew its position in shares of Ginkgo Bioworks by 667.6% in the first quarter. CWM LLC now owns 12,274 shares of the company's stock valued at $70,000 after purchasing an additional 10,675 shares during the period. Fox Run Management L.L.C. acquired a new position in Ginkgo Bioworks during the first quarter worth about $76,000. Finally, Green Alpha Advisors LLC boosted its position in Ginkgo Bioworks by 31.7% during the first quarter. Green Alpha Advisors LLC now owns 18,470 shares of the company's stock worth $105,000 after acquiring an additional 4,449 shares during the last quarter. 78.63% of the stock is currently owned by institutional investors.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.